|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013216,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0031928,
umls-concept:C0040808,
umls-concept:C0078257,
umls-concept:C0205225,
umls-concept:C0205251,
umls-concept:C0332256,
umls-concept:C0439655,
umls-concept:C1407029,
umls-concept:C1514474,
umls-concept:C2828008
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1999-11-16
|
|
pubmed:abstractText |
Biological considerations support the use of primary chemotherapy in operable breast cancer; and despite wide variations of used regimens, clinical studies consistently show a significant tumor response allowing breast conservation in many patients otherwise candidates for mastectomy. We investigated the efficacy and the acceptance of a combination chemotherapy with vinorelbine, 5-fluorouracil and high-dose folinic acid in operable breast cancer with favorable prognostic factors and tested the relationship of hormone receptor status, Ki67,p53, c-erbB2 and bcl-2 with treatment response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:CataniaCC,
pubmed-author:ColleoniMM,
pubmed-author:GalimbertiVV,
pubmed-author:GoldhirschAA,
pubmed-author:MartinelliGG,
pubmed-author:MinchellaII,
pubmed-author:MunzoneEE,
pubmed-author:NolèFF,
pubmed-author:OrvietoEE,
pubmed-author:PeruzzottiGG,
pubmed-author:PizzamiglioMM,
pubmed-author:VeronesiPP,
pubmed-author:VeronesiUU,
pubmed-author:ZampinoM GMG,
pubmed-author:ZurridaSS,
pubmed-author:de BraudFF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
993-6
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10509165-Adult,
pubmed-meshheading:10509165-Aged,
pubmed-meshheading:10509165-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10509165-Biopsy,
pubmed-meshheading:10509165-Breast Neoplasms,
pubmed-meshheading:10509165-Disease-Free Survival,
pubmed-meshheading:10509165-Dose-Response Relationship, Drug,
pubmed-meshheading:10509165-Drug Administration Schedule,
pubmed-meshheading:10509165-Female,
pubmed-meshheading:10509165-Fluorouracil,
pubmed-meshheading:10509165-Humans,
pubmed-meshheading:10509165-Leucovorin,
pubmed-meshheading:10509165-Middle Aged,
pubmed-meshheading:10509165-Neoplasm Staging,
pubmed-meshheading:10509165-Pilot Projects,
pubmed-meshheading:10509165-Prognosis,
pubmed-meshheading:10509165-Receptors, Estrogen,
pubmed-meshheading:10509165-Receptors, Progesterone,
pubmed-meshheading:10509165-Survival Rate,
pubmed-meshheading:10509165-Treatment Outcome,
pubmed-meshheading:10509165-Vinblastine
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
|
|
pubmed:affiliation |
Division of Medical Oncology, European Institute of Oncology, Milan, Italy. fnole@ieo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
